IASO Biotechnology announced that the U.S. Food and Drug Administration has approved the Investigational New Drug application for its IASO-782 Injection for use in U.S. clinical trials for Autoimmune hematological disorders, including primary immune thrombocytopenia and warm autoimmune hemolytic anemia.
